MA50375A - Compositions contenant des composés substitués de [1,2,4]triazolo[1,5-a]pyrimidine-7-yl utilisés en tant qu'inhibiteurs pde2 - Google Patents

Compositions contenant des composés substitués de [1,2,4]triazolo[1,5-a]pyrimidine-7-yl utilisés en tant qu'inhibiteurs pde2

Info

Publication number
MA50375A
MA50375A MA050375A MA50375A MA50375A MA 50375 A MA50375 A MA 50375A MA 050375 A MA050375 A MA 050375A MA 50375 A MA50375 A MA 50375A MA 50375 A MA50375 A MA 50375A
Authority
MA
Morocco
Prior art keywords
triazolo
pyrimidine
compositions containing
compounds used
pde2 inhibitors
Prior art date
Application number
MA050375A
Other languages
English (en)
Inventor
James Breitenbucher
Graeme Freestone
Laurent Gomez
Robert Lemus
Kiev Ly
Margaret Mccarrick
William Vernier
Troy Vickers
Original Assignee
Dart Neuroscience Cayman Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dart Neuroscience Cayman Ltd filed Critical Dart Neuroscience Cayman Ltd
Publication of MA50375A publication Critical patent/MA50375A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/50—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving creatine phosphokinase

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA050375A 2014-04-23 2015-04-22 Compositions contenant des composés substitués de [1,2,4]triazolo[1,5-a]pyrimidine-7-yl utilisés en tant qu'inhibiteurs pde2 MA50375A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461983387P 2014-04-23 2014-04-23

Publications (1)

Publication Number Publication Date
MA50375A true MA50375A (fr) 2021-05-26

Family

ID=53055118

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050375A MA50375A (fr) 2014-04-23 2015-04-22 Compositions contenant des composés substitués de [1,2,4]triazolo[1,5-a]pyrimidine-7-yl utilisés en tant qu'inhibiteurs pde2

Country Status (23)

Country Link
US (5) US9932345B2 (fr)
EP (2) EP3134413B1 (fr)
JP (1) JP6626449B2 (fr)
KR (1) KR102471058B1 (fr)
CN (2) CN110092788B (fr)
AU (2) AU2015249753B2 (fr)
BR (1) BR112016024713B1 (fr)
CA (1) CA2938294C (fr)
DK (2) DK3597649T3 (fr)
ES (2) ES2902806T3 (fr)
HR (1) HRP20212035T1 (fr)
HU (1) HUE057317T2 (fr)
IL (2) IL248292A (fr)
MA (1) MA50375A (fr)
MX (1) MX358004B (fr)
NZ (1) NZ725161A (fr)
PL (1) PL3597649T3 (fr)
PT (1) PT3597649T (fr)
RU (1) RU2659070C9 (fr)
SG (1) SG11201606216UA (fr)
SI (1) SI3597649T1 (fr)
TW (1) TWI664181B (fr)
WO (1) WO2015164508A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE057317T2 (hu) 2014-04-23 2022-04-28 Dart Neuroscience Llc Helyettesített [1,2,4]triazolo[1,5-A]pirimidin-7-IL vegyületeket tartalmazó készítmények mint PDE2 inhibítorok
EP3868752A1 (fr) 2014-08-28 2021-08-25 Asceneuron SA Inhibiteurs de la glycosidase
TWI568737B (zh) * 2014-11-05 2017-02-01 達特神經科學（開曼）有限責任公司 作為ｐｄｅ２抑制劑之經取代的５－甲基－［１，２，４］三唑并［１，５－ａ］嘧啶－２－胺化合物
ES2765738T3 (es) * 2015-11-02 2020-06-10 Janssen Pharmaceutica Nv Compuesto de [1,2,4]triazolo[1,5-a]pirimidin-7-ilo
US11261183B2 (en) 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
CN108884078A (zh) 2016-02-25 2018-11-23 阿森纽荣股份公司 糖苷酶抑制剂
SG11201807012QA (en) 2016-02-25 2018-09-27 Asceneuron S A Acid addition salts of piperazine derivatives
AU2017222958B2 (en) 2016-02-25 2019-07-18 Asceneuron S. A. Glycosidase inhibitors
AU2017353313C1 (en) * 2016-11-02 2022-06-09 Janssen Pharmaceutica Nv (1,2,4)triazolo(1,5-a)pyrimidine compounds as PDE2 inhibitors
MX385576B (es) * 2016-11-02 2025-03-18 Janssen Pharmaceutica Nv Derivados de [1,2,4]triazol[1,5-a]pirimidina como inhibidores de pde2
CA3038916A1 (fr) 2016-11-02 2018-05-11 Janssen Pharmaceutica Nv Composes de [1,2,4]triazolo[1,5-a]pyrimidine en tant qu'inhibiteurs de pde2
US20190359609A1 (en) * 2016-12-16 2019-11-28 Janssen Pharmaceutica Nv Bicyclic oga inhibitor compounds
WO2018154133A1 (fr) 2017-02-27 2018-08-30 Janssen Pharmaceutica Nv Dérivés de [1,2,4]-triazolo [1,5-a]-pyrimidinyle substitués par de la pipéridine, de la morpholine ou de la pipérazine utilisés en tant qu'inhibiteurs d'oga
WO2019037860A1 (fr) 2017-08-24 2019-02-28 Asceneuron S.A. Inhibiteurs linéaires de la glycosidase
WO2020039028A1 (fr) 2018-08-22 2020-02-27 Asceneuron S. A. Inhibiteurs de tétrahydro-benzoazépine glycosidase
WO2020039029A1 (fr) 2018-08-22 2020-02-27 Asceneuron S. A. Composés spiro utilisés en tant qu'inhibiteurs de glycosidases
WO2020039027A1 (fr) 2018-08-22 2020-02-27 Asceneuron S. A. Inhibiteurs de pyrrolidine glycosidase
IL280841B2 (en) 2018-08-22 2024-12-01 Asceneuron S A Succinate and fumarate acid addition salts of piperazine derivatives useful as glycosidase inhibitors
WO2020231723A1 (fr) 2019-05-13 2020-11-19 Ecolab Usa Inc. 1,2,4-triazolo[1,5-a] dérivé de la pyrimidine comme inhibiteur de corrosion du cuivre
TWI907472B (zh) 2020-08-05 2025-12-11 匈牙利商羅特格登公司 具藥理活性之經雜環取代的吡唑并〔１，５－ａ〕嘧啶衍生物

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2510111A1 (fr) * 1981-07-24 1983-01-28 Roussel Uclaf Nouveaux derives du piperidin-3-yl indole, leurs sels, leur procede de preparation, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5478825A (en) 1991-02-22 1995-12-26 Egis Gyogyszergyar 5-(substituted amino)-1,2,4-triazolo (1,5-A) pyrimidine derivatives
HU208693B (en) 1991-02-22 1993-12-28 Egyt Gyogyszervegyeszeti Gyar Process for producing 1,2,4-triazolo (1,5-a) pyrimidinis derivatives and their carbicycli-tetrahydro-thiofurane-tetrahydrothiopyrane-, or tetrahydropyridine- condensated derivatives or medical preparatives containing them
US7868015B2 (en) 2000-08-10 2011-01-11 Cold Spring Harbor Laboratory Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
US9931318B2 (en) 2003-04-08 2018-04-03 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
EP2316531A1 (fr) 2000-08-10 2011-05-04 Cold Spring Harbor Laboratory Apprentissage cognitif amélioré
DE10064105A1 (de) 2000-12-21 2002-06-27 Bayer Ag Neue Substituierte Imidazotriazinone
WO2002064211A1 (fr) 2001-02-09 2002-08-22 Merck & Co., Inc. Inhibiteurs de thrombine
DE10108752A1 (de) 2001-02-23 2002-09-05 Bayer Ag Neue Substituierte Imidazotriazinone
FR2832711B1 (fr) * 2001-11-26 2004-01-30 Warner Lambert Co Derives de triazolo [4,3-a] pyrido [2,3-d] pyrimidin-5-ones, compositions les contenant, procede de preparation et utilisation
EP1597386A1 (fr) 2002-11-13 2005-11-23 Bayer HealthCare AG Outils de diagnostics et therapeutique pour maladies associees a la phosphodiesterase 2a humaine (pde2a)
EP1644003A1 (fr) 2003-06-04 2006-04-12 Vernalis (Cambridge) Limited Triazolo ´1,5-a!pyrimidines et leur utilisation en medecine
WO2005041957A1 (fr) 2003-10-29 2005-05-12 Pfizer Products Inc. Derives d'oxindole et leur utilisation comme inhibiteurs de la phosphodiesterase de type 2
DE10356579A1 (de) 2003-12-04 2005-07-07 Merck Patent Gmbh Aminderivate
EP1548011A1 (fr) 2003-12-23 2005-06-29 Neuro3D Dérivés de 1,4-benzodiazépine-2-one comme inhibiteurs de PDE2 phosphodiesterase, leurs préparation et utilisation thérapeutique
KR101368093B1 (ko) 2004-09-02 2014-03-14 다케다 게엠베하 트리아졸로프탈라진
CA2591991C (fr) 2005-01-05 2013-11-19 Altana Pharma Ag Triazolophthalazines
CN101103033B (zh) 2005-01-05 2010-08-04 尼科梅德有限责任公司 作为pde2抑制剂的三唑并酞嗪
US7868016B2 (en) 2005-07-13 2011-01-11 Baxter International Inc. Pharmaceutical formulations of endo-N-(9-methyl-9-azabicyclo[3,3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride
CN101321758A (zh) * 2005-10-03 2008-12-10 阿斯利康(瑞典)有限公司 用于治疗哮喘和慢性阻塞性肺病的新5,6－二氢吡唑并[3,4－e][1,4]二氮杂－4(1H)－酮衍生物
KR100844125B1 (ko) 2007-03-23 2008-07-04 한국화학연구원 7-(3′,4′-디알콕시페닐)-[1,2,4]트리아졸로[1,5-ａ]피리미딘 화합물, 이의 제조방법 및 이를 포함하는 천식 및만성폐쇄성 폐질환을 포함한 염증관련 질환, 관절염,아토피 피부염, 암 및 뇌질환의 치료 및 예방을 위한약제학적 조성물
BRPI0811623A2 (pt) 2007-05-15 2014-11-11 Helicon Therapeutics Inc Métodos para identificar genes envolvidos na formação de memória usando pequeno rna interferente (sirna)
TWI501965B (zh) 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物
WO2010054253A1 (fr) 2008-11-07 2010-05-14 Biotie Therapies Gmbh Dérivés de triazine en tant qu’inhibiteurs de phosphodiestérases
WO2010054260A1 (fr) 2008-11-07 2010-05-14 Biotie Therapies Gmbh Dérivés d'imidazo[5,1-c][1,2,4]benzotriazine en tant qu'inhibiteurs de phosphodiestérases
PT2414363E (pt) 2009-03-31 2014-02-26 Boehringer Ingelheim Int Derivados de 1-heterociclil-1,5-di-hidro-pirazolo[3,4- d]pirimidin-4-ona e sua utilização como moduladores de pde9a
US8680116B2 (en) 2009-07-22 2014-03-25 Merck Sharp & Dohme Corp. Quinolinone PDE2 inhibitors
WO2012080729A2 (fr) * 2010-12-14 2012-06-21 Electrophoretics Limited Inhibiteurs de caséine kinase 1δ (ck1δ)
US9540379B2 (en) 2011-01-31 2017-01-10 Boehringer Ingelheim International Gmbh (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases
KR101548443B1 (ko) * 2011-02-23 2015-08-28 화이자 인코포레이티드 신경 장애의 치료를 위한 이미다조[5,1-f][1,2,4]트라이아진
CA2836851C (fr) 2011-06-07 2016-06-21 Christopher J. Helal Composes pyrazolo[3,4-d]pyrimidine et leur utilisation comme inhibiteurs de la pde2 et/ou inhibiteurs du cyp3a4
WO2013000924A1 (fr) 2011-06-27 2013-01-03 Janssen Pharmaceutica Nv Dérivés de 1-aryl-4-méthyl-[1,2,4]triazolo[4,3-a]quinoxaline
WO2013034755A1 (fr) 2011-09-09 2013-03-14 H. Lundbeck A/S Dérivés de triazolopyrazine et leur utilisation pour le traitement de troubles neurologiques et psychiatriques
WO2013034758A1 (fr) 2011-09-09 2013-03-14 H. Lundbeck A/S Triazolopyrazines substituées et leurs utilisations
EP2763989A1 (fr) 2011-09-09 2014-08-13 H. Lundbeck A/S Composés de pyridine et leurs utilisations
US20130116241A1 (en) * 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a
CN103183675A (zh) * 2011-12-27 2013-07-03 山东轩竹医药科技有限公司 磷酸二酯酶-4抑制剂
JPWO2015012328A1 (ja) 2013-07-24 2017-03-02 武田薬品工業株式会社 複素環化合物
HUE057317T2 (hu) 2014-04-23 2022-04-28 Dart Neuroscience Llc Helyettesített [1,2,4]triazolo[1,5-A]pirimidin-7-IL vegyületeket tartalmazó készítmények mint PDE2 inhibítorok
TWI568737B (zh) 2014-11-05 2017-02-01 達特神經科學（開曼）有限責任公司 作為ｐｄｅ２抑制劑之經取代的５－甲基－［１，２，４］三唑并［１，５－ａ］嘧啶－２－胺化合物

Also Published As

Publication number Publication date
US9932345B2 (en) 2018-04-03
TW201625625A (zh) 2016-07-16
CN106459062A (zh) 2017-02-22
HRP20212035T1 (hr) 2022-04-01
US20180179216A1 (en) 2018-06-28
EP3597649A1 (fr) 2020-01-22
EP3597649B8 (fr) 2022-02-16
JP6626449B2 (ja) 2019-12-25
PT3597649T (pt) 2022-01-21
SG11201606216UA (en) 2016-09-29
CN110092788A (zh) 2019-08-06
KR102471058B1 (ko) 2022-11-25
AU2019283994B2 (en) 2021-05-27
RU2659070C9 (ru) 2018-08-24
BR112016024713B1 (pt) 2023-05-02
BR112016024713A2 (pt) 2017-08-15
JP2017513808A (ja) 2017-06-01
CA2938294C (fr) 2023-02-21
AU2015249753A1 (en) 2016-11-03
AU2019283994C1 (en) 2021-12-09
AU2015249753B2 (en) 2019-10-10
RU2016143387A3 (fr) 2018-05-23
US11186582B2 (en) 2021-11-30
KR20160145745A (ko) 2016-12-20
ES2759246T3 (es) 2020-05-08
CA2938294A1 (fr) 2015-10-29
CN110092788B (zh) 2022-02-25
WO2015164508A4 (fr) 2015-12-23
US10501465B2 (en) 2019-12-10
MX358004B (es) 2018-07-31
NZ725161A (en) 2017-10-27
IL254224A0 (en) 2017-10-31
US20250092047A1 (en) 2025-03-20
AU2019283994A1 (en) 2020-01-23
EP3134413B1 (fr) 2019-09-11
ES2902806T3 (es) 2022-03-29
DK3134413T3 (da) 2019-10-14
IL254224B (en) 2019-01-31
EP3134413A1 (fr) 2017-03-01
SI3597649T1 (sl) 2022-04-29
US20200095256A1 (en) 2020-03-26
TWI664181B (zh) 2019-07-01
PL3597649T3 (pl) 2022-04-04
RU2016143387A (ru) 2018-05-23
IL248292A (en) 2017-09-28
HUE057317T2 (hu) 2022-04-28
EP3597649B1 (fr) 2021-10-13
RU2659070C2 (ru) 2018-06-28
WO2015164508A1 (fr) 2015-10-29
US20230192698A1 (en) 2023-06-22
US20170057967A1 (en) 2017-03-02
DK3597649T3 (da) 2022-01-10
MX2016013860A (es) 2017-05-12

Similar Documents

Publication Publication Date Title
MA50375A (fr) Compositions contenant des composés substitués de [1,2,4]triazolo[1,5-a]pyrimidine-7-yl utilisés en tant qu'inhibiteurs pde2
CL2019000942A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
MA52987A (fr) Dérivés de pyrazolo[1,5-a]pyrazin-4-yl en tant qu'inhibiteurs de jak
EP3328840A4 (fr) Composés bicycliques triazolo substitués en tant qu'inhibiteurs de pde2
MA53675A (fr) Composés substitués de pyrazolo[1,5-a]pyridine en tant qu'inhibiteurs de la kinase ret
MA49570A (fr) Composés bicycliques pyrazolo et triazolo utilisés en tant qu'inhibiteurs de kinase jak
MA41551A (fr) Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
ZA201700737B (en) Cyclohexyl-ethyl substituted diaza- and triaza-tricyclic compounds as indole-amine-2,3-dioxygenase (ido) antagonists for the treatment of cancer
SI3107914T1 (sl) Pirazolo(1,5-A)pirimidin-5,7-diaminske spojine kot inhibitorji CDK in njihova terapevtska uporaba
DK3322706T3 (da) Substituerede pyrazolo[1,5-a]pyridin-forbindelser som ret-kinaseinhibitorer
TW201613925A (en) Imidazopyrazines as LSD1 inhibitors
MA42919A (fr) Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
MA43169A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
IL266305B (en) History of [4,2,1]triazolo[5,1-a]pyrimidine as pde2 inhibitors
EA202191301A1 (ru) СОСТАВ ТАБЛЕТОК 2-ФТОР-N-МЕТИЛ-4-[7-(ХИНОЛИН-6-ИЛМЕТИЛ)ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИН-2-ИЛ]БЕНЗАМИДА
EA201891251A1 (ru) Бициклические ингибиторы pad4
ZA201607736B (en) Analogs of 4h-pyrazolo[1,5-a]benzimidazole compounds as parp inhibitors
MA42918A (fr) Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
ME03672B (fr) 1h-pyrazolo [4,3-b]pyridines en tant qu'inhibiteurs de pde1
EP3319966A4 (fr) Composés hétérocycliques bicycliques utilisés comme inhibiteurs de pde2
MA46690A (fr) Composés de [1,2,4]triazolo [1,5-a]pyrimidine en tant qu'inhibiteurs de pde2
CL2016000496A1 (es) Compuestos derivados de 1,2,4-triazolo[1,5-a]-piridina, inhibidores de una janus cinasa, tal como jak1; composiciones farmacológicas; útiles para el tratamiento de enfermedades inflamatorias.
ZA201605666B (en) Pyrazolo[1,5-a]pyrimidines as antiviral compounds
EA201690716A1 (ru) ПИРИДО[2,3-d]ПИРИМИДИН-4-ОНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ ТАНКИРАЗЫ
EP3551630A4 (fr) Dérivés d'imidazo [1,5-a]pyrazine en tant qu'inhibiteurs de pi3kdelta